Affiliation:
1. From the Departments of Palliative Care and Rehabilitation Medicine, Breast Medical Oncology, and Anesthesiology and Pain Medicine, The University of Texas M.D. Anderson Cancer Center, and The Lyndon B. Johnson General Hospital, Houston, TX
Abstract
Purpose To evaluate the effectiveness of patient-controlled methylphenidate as compared with placebo in cancer patients with fatigue, as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F). Patients and Methods Patients with a fatigue score of at least 4 on a scale of 0 to 10 (0 = no fatigue, 10 = worst possible fatigue) and hemoglobin level of at least 10 g/dL were included. Patients were randomly assigned to receive 5 mg methylphenidate or placebo every 2 hours as needed (maximum of four capsules a day), for 7 days. Patients completed a daily diary including study drug record and fatigue intensity. A research nurse telephoned patients daily to assess toxicity and fatigue level. All patients were offered open-label methylphenidate for 4 weeks. FACIT-F and the Edmonton Symptom Assessment System (ESAS) were assessed at baseline, and days 8, 15, and 36. The FACIT-F fatigue subscore on day 8 was considered the primary end point. Results Of 112 patients randomly assigned, 52 patients in the methylphenidate and 53 in the placebo group were assessable for analysis. Fatigue intensity improved significantly on day 8 in both the methylphenidate and placebo groups. However, there was no significant difference in fatigue improvement by FACIT-F (P = .31) or ESAS (P = .14) between groups. In open-label phase, fatigue intensity maintained low as compared with baseline. No significant toxicities were observed. Conclusion Both methylphenidate and placebo resulted in significant symptom improvement. Methylphenidate was not significantly superior to placebo after 1 week of treatment. Longer study duration is justified. The role of daily telephone calls from a research nurse should be explored as a palliative care intervention.
Publisher
American Society of Clinical Oncology (ASCO)
Reference28 articles.
1. Vogelzang N, Breitbart W, Cella D, et al: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tri-part assessment survey. Semin Hematol 34:4,1997-12, (suppl 2)
2. Mock V, Piper B, Sabbatini P, et al: National Comprehensive Cancer Network fatigue guidelines. Oncology (Williston Park) 14:151,2000-161,
3. Multidimensional independent predictors of cancer-related fatigue
4. Fatigue in advanced cancer: a prospective controlled cross-sectional study
5. Fatigue in patients with advanced cancer: A review
Cited by
246 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献